https://www.biospace.com/corcept-therapeutics-announces-presentations-of-results-of-pivotal-phase-3-grace-trial-evaluating-relacorilant-in-patients-with-hypercortisolism-cushing-s-syndrome
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating...
Jun 3, 2024 - Corcept Therapeutics Incorporated today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant...
presentations of resultstherapeuticsannouncespivotalphase